
ENGN Stock Forecast & Price Target
ENGN Analyst Ratings
Bulls say
enGene Holdings Inc. is in a strong position for future growth due to the receipt of RMAT designation for its lead product, detalimogene, which is expected to enhance its market share, particularly in community practice settings. The company has identified additional opportunity for expansion through its LEGEND study cohorts, which could broaden the addressable market by including earlier disease stages and active surveillance. Although research and development expenses have risen significantly to $22.6 million in 3Q25, this increase reflects the commitment to advancing its clinical trials and manufacturing capabilities, essential for long-term product development success.
Bears say
A negative outlook on enGene Holdings's stock is primarily driven by the risk of failing to achieve regulatory approval or facing delays in approval timelines, which could significantly impact the company’s share price. Additionally, the operational challenges associated with the TAR-200 product, including a 24% serious adverse event rate and approximately 7% discontinuation rate, may hinder its market adoption and overall commercial success. Finally, any dissatisfaction with TAR-200's operational burden could further accelerate the competitive uptake of detalimogene, posing additional risks to enGene’s market position.
This aggregate rating is based on analysts' research of Engene Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
ENGN Analyst Forecast & Price Prediction
Start investing in ENGN
Order type
Buy in
Order amount
Est. shares
0 shares